Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is overvalued on P/FCF.
Target Price
The average target price of CERS is 4.8 and suggests 119% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell